FI114443B - Menetelmä mikrobisidaalisen silmälääkeliuoksen valmistamiseksi - Google Patents
Menetelmä mikrobisidaalisen silmälääkeliuoksen valmistamiseksi Download PDFInfo
- Publication number
- FI114443B FI114443B FI922906A FI922906A FI114443B FI 114443 B FI114443 B FI 114443B FI 922906 A FI922906 A FI 922906A FI 922906 A FI922906 A FI 922906A FI 114443 B FI114443 B FI 114443B
- Authority
- FI
- Finland
- Prior art keywords
- solution
- iodine
- amount
- pvp
- months
- Prior art date
Links
- 230000003641 microbiacidal effect Effects 0.000 title claims abstract description 12
- 239000002997 ophthalmic solution Substances 0.000 title claims description 23
- 229940054534 ophthalmic solution Drugs 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title description 4
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 103
- 239000011630 iodine Substances 0.000 claims abstract description 101
- 229910052740 iodine Inorganic materials 0.000 claims abstract description 101
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 32
- 239000011521 glass Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 19
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 152
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 36
- 230000003113 alkalizing effect Effects 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 229920000153 Povidone-iodine Polymers 0.000 claims description 13
- -1 iodine ions Chemical class 0.000 claims description 13
- 231100000344 non-irritating Toxicity 0.000 claims description 12
- 229960001621 povidone-iodine Drugs 0.000 claims description 12
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000003732 agents acting on the eye Substances 0.000 claims description 8
- 229940023490 ophthalmic product Drugs 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 2
- 235000019800 disodium phosphate Nutrition 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 235000012976 tarts Nutrition 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 1
- FAAHNQAYWKTLFD-UHFFFAOYSA-N 1-butan-2-ylpyrrolidin-2-one Chemical compound CCC(C)N1CCCC1=O FAAHNQAYWKTLFD-UHFFFAOYSA-N 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 86
- 235000013675 iodine Nutrition 0.000 description 86
- 230000008859 change Effects 0.000 description 17
- 230000000845 anti-microbial effect Effects 0.000 description 11
- 229940012356 eye drops Drugs 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 229920003102 Methocel™ E4M Polymers 0.000 description 7
- 229940064804 betadine Drugs 0.000 description 7
- 239000003889 eye drop Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QSDSSSQWVNLFIG-UHFFFAOYSA-N Neosporin Natural products CC(O)CC1=C(OC)C(=O)C2=CC(O)=C3OCOC4=C(O)C=C5C6=C4C3=C2C1=C6C(CC(C)O)=C(OC)C5=O QSDSSSQWVNLFIG-UHFFFAOYSA-N 0.000 description 5
- 108010046161 drug combination polymyxin B neomycin sulfate bacitracin zinc Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940072360 garamycin Drugs 0.000 description 5
- 229940049337 neosporin Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 229920000620 organic polymer Polymers 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000005361 soda-lime glass Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 244000038458 Nepenthes mirabilis Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- 229940006461 iodide ion Drugs 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 240000007524 Camellia sinensis var. sinensis Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010010725 Conjunctival irritation Diseases 0.000 description 1
- 206010056476 Corneal irritation Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000200696 Halictus simplex Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Lubricants (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73046291 | 1991-07-16 | ||
| US07/730,462 US5126127A (en) | 1991-07-16 | 1991-07-16 | Stabilized PVP-I solutions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI922906A0 FI922906A0 (fi) | 1992-06-22 |
| FI922906A FI922906A (fi) | 1993-01-17 |
| FI114443B true FI114443B (fi) | 2004-10-29 |
Family
ID=24935466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI922906A FI114443B (fi) | 1991-07-16 | 1992-06-22 | Menetelmä mikrobisidaalisen silmälääkeliuoksen valmistamiseksi |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5126127A (no) |
| EP (1) | EP0526695B1 (no) |
| JP (1) | JP3531945B2 (no) |
| KR (1) | KR100191873B1 (no) |
| AT (1) | ATE163130T1 (no) |
| AU (1) | AU646745B2 (no) |
| CA (1) | CA2062001C (no) |
| DE (1) | DE69224416T2 (no) |
| DK (1) | DK0526695T3 (no) |
| EG (1) | EG19995A (no) |
| ES (1) | ES2111581T3 (no) |
| FI (1) | FI114443B (no) |
| IE (1) | IE920796A1 (no) |
| IL (1) | IL101079A (no) |
| NO (1) | NO306379B1 (no) |
| ZA (1) | ZA921365B (no) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006911A1 (en) * | 1991-10-08 | 1993-04-15 | Isp Investments Inc. | Method of treating blood |
| GB9306296D0 (en) * | 1993-03-26 | 1993-05-19 | Diversey Corp | Improved iodophors,production and use thereof |
| DE9312509U1 (de) * | 1993-08-20 | 1993-10-28 | Euro-Celtique S.A., Luxemburg/Luxembourg | Präparate zur äußeren Verabreichung von antiseptischen und/oder die Wundheilung fördernden Wirkstoffen |
| JP3108262B2 (ja) * | 1993-12-22 | 2000-11-13 | 明治製菓株式会社 | 研磨剤を含有しない口腔用半練状製剤 |
| US6605110B2 (en) | 2001-06-29 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent with enhanced bendability and flexibility |
| PT1479379E (pt) | 2003-05-19 | 2007-10-23 | Euro Celtique Sa | ''composições lipossomais secas de pvp-iodo'' |
| US20050262811A1 (en) * | 2004-05-27 | 2005-12-01 | Mahmood Mohiuddin | Sterilization process for iodine-containing antimicrobial topical solutions |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| AU2013203462B2 (en) * | 2006-03-14 | 2016-08-04 | Cls Pharmaceuticals, Inc. | Ophthalmic compositions comprising povidone-iodine |
| AU2016253668B2 (en) * | 2006-03-14 | 2018-12-06 | Cls Pharmaceuticals, Inc. | Ophthalmic compositions comprising povidone-iodine |
| JP5083502B2 (ja) * | 2006-12-25 | 2012-11-28 | ライオン株式会社 | 眼科用組成物 |
| US20080172032A1 (en) * | 2007-01-11 | 2008-07-17 | James Pitzer Gills | Method for preventing tissue damage associated with irrigation of tissue with an antimicrobial solution |
| US20120027716A1 (en) * | 2008-06-12 | 2012-02-02 | Foresight Biotherapeutics, Inc. | Povidone Iodine, A Novel Alternative Preservative For Ophthalmic Compositions |
| EP2512230A4 (en) * | 2009-12-15 | 2013-05-22 | Foresight Biotherapeutics Inc | NON-REFRACTORY OPHTHALMIC POVIDONE IOD COMPOSITIONS |
| JP5367597B2 (ja) | 2010-01-18 | 2013-12-11 | 株式会社オフテクス | コンタクトレンズ洗浄用有核錠及びそれを含むコンタクトレンズ洗浄用製剤、並びにコンタクトレンズ洗浄方法 |
| GB201114725D0 (en) * | 2011-08-25 | 2011-10-12 | Altacor Ltd | Ophthalmic formulations |
| TW201808311A (zh) * | 2011-09-16 | 2018-03-16 | 遠景生物製藥股份有限公司 | 安定之普維酮-碘組成物 |
| KR102171897B1 (ko) | 2012-09-12 | 2020-11-02 | 노바리크 게엠베하 | 부분불소화 알칸 조성물 |
| DE202013012742U1 (de) | 2012-09-12 | 2019-01-22 | Novaliq Gmbh | Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen |
| US20180200289A1 (en) * | 2015-07-02 | 2018-07-19 | Veloce Biopharma, Llc | Novel ophthalmic composition and methods of use |
| US9770466B2 (en) | 2015-07-02 | 2017-09-26 | Veloce Biopharma, Llc | Ophthalmic composition and methods of use |
| ES2957559T3 (es) * | 2017-04-21 | 2024-01-22 | Dermaliq Therapeutics Inc | Composiciones de yodo |
| IT201700068170A1 (it) * | 2017-06-20 | 2018-12-20 | Iromed Group S R L | Composizione disinfettante per uso oftalmico |
| WO2019040051A1 (en) * | 2017-08-22 | 2019-02-28 | Veloce Biopharma, Llc | NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USE |
| WO2019046844A1 (en) | 2017-09-02 | 2019-03-07 | Iview Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS FORMING IN SITU A GEL AND THEIR USES FOR SINUS DISEASES |
| AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| KR20200081160A (ko) | 2018-12-27 | 2020-07-07 | 유한회사 플루켐 | 염화나트륨 함유 포비돈 요오드 안정 조성물 및 방법 |
| AU2020280226A1 (en) | 2019-06-10 | 2022-01-06 | Firebrick Pharma Limited | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes |
| WO2021034421A1 (en) * | 2019-08-18 | 2021-02-25 | Iview Therapeutics, Inc. | Stable pharmaceutical articles containing dilute povidone iodine formulations |
| EP4171583A4 (en) * | 2020-06-10 | 2024-06-26 | Firebrick Pharma Limited | IMPROVED VIRUCIDAL FORMULATIONS |
| AU2021203846B2 (en) * | 2021-06-10 | 2022-11-24 | Firebrick Pharma Limited | Virucidal formulations containing povidone-iodine |
| KR102434736B1 (ko) | 2021-11-04 | 2022-08-23 | (주)씨에스하이테크플러스 | 신재생에너지를 이용한 에너지자립형 냉난방 시스템 및 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4364929A (en) * | 1979-04-02 | 1982-12-21 | The Purdue Frederick Company | Germicidal colloidal lubricating gels and method of producing the same |
| SE7902893L (sv) * | 1979-04-02 | 1980-10-03 | Astra Chem Prod Ab | Desinfektionsmedel |
| US4401651A (en) * | 1979-04-18 | 1983-08-30 | Knutson Richard A | Wound-healing compositions containing povidone-iodine |
| US4526751A (en) * | 1983-12-09 | 1985-07-02 | Gartner William J | Germicidal solutions effective for solid surface disinfection |
| WO1989000044A1 (en) * | 1987-07-07 | 1989-01-12 | Santen Pharmaceutical Co., Ltd. | Artificial lacrima |
| CA1303503C (en) * | 1987-11-10 | 1992-06-16 | Marc Plamondon | Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex |
| DE3882042T2 (de) * | 1987-12-25 | 1993-09-30 | Santen Pharma Co Ltd | Antiallergische augentropfen. |
| US4939272A (en) * | 1989-05-05 | 1990-07-03 | Gaf Chemicals Corporation | Water soluble complexes of polyvinylpyrrolidone, hydrogen chloride and iodine and process for making the same |
| NL9002049A (nl) * | 1990-09-18 | 1992-04-16 | Dagra Pharma Bv | Oogheelkundig preparaat dat een povidon-joodoplossing bevat. |
-
1991
- 1991-07-16 US US07/730,462 patent/US5126127A/en not_active Expired - Lifetime
-
1992
- 1992-02-25 ZA ZA921365A patent/ZA921365B/xx unknown
- 1992-02-27 IL IL10107992A patent/IL101079A/xx not_active IP Right Cessation
- 1992-02-27 CA CA002062001A patent/CA2062001C/en not_active Expired - Fee Related
- 1992-03-12 IE IE079692A patent/IE920796A1/en not_active IP Right Cessation
- 1992-03-23 JP JP06448592A patent/JP3531945B2/ja not_active Expired - Fee Related
- 1992-04-15 DK DK92106500T patent/DK0526695T3/da active
- 1992-04-15 EP EP92106500A patent/EP0526695B1/en not_active Expired - Lifetime
- 1992-04-15 AT AT92106500T patent/ATE163130T1/de not_active IP Right Cessation
- 1992-04-15 DE DE69224416T patent/DE69224416T2/de not_active Expired - Fee Related
- 1992-04-15 ES ES92106500T patent/ES2111581T3/es not_active Expired - Lifetime
- 1992-06-15 KR KR1019920010355A patent/KR100191873B1/ko not_active IP Right Cessation
- 1992-06-22 FI FI922906A patent/FI114443B/fi not_active IP Right Cessation
- 1992-07-02 AU AU19427/92A patent/AU646745B2/en not_active Ceased
- 1992-07-14 EG EG39192A patent/EG19995A/xx active
- 1992-07-15 NO NO922793A patent/NO306379B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE920796A1 (en) | 1993-01-27 |
| EP0526695A1 (en) | 1993-02-10 |
| NO922793L (no) | 1993-01-18 |
| ATE163130T1 (de) | 1998-02-15 |
| AU1942792A (en) | 1994-01-13 |
| EP0526695B1 (en) | 1998-02-11 |
| FI922906A0 (fi) | 1992-06-22 |
| IL101079A (en) | 1997-01-10 |
| FI922906A (fi) | 1993-01-17 |
| NO922793D0 (no) | 1992-07-15 |
| CA2062001C (en) | 1999-03-02 |
| CA2062001A1 (en) | 1993-01-17 |
| DK0526695T3 (da) | 1998-09-23 |
| JPH0570356A (ja) | 1993-03-23 |
| NO306379B1 (no) | 1999-11-01 |
| ZA921365B (en) | 1992-11-25 |
| IL101079A0 (en) | 1992-11-15 |
| DE69224416T2 (de) | 1998-07-30 |
| DE69224416D1 (de) | 1998-03-19 |
| US5126127A (en) | 1992-06-30 |
| EG19995A (en) | 1997-01-30 |
| KR100191873B1 (ko) | 1999-06-15 |
| ES2111581T3 (es) | 1998-03-16 |
| KR930001914A (ko) | 1993-02-22 |
| JP3531945B2 (ja) | 2004-05-31 |
| AU646745B2 (en) | 1994-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114443B (fi) | Menetelmä mikrobisidaalisen silmälääkeliuoksen valmistamiseksi | |
| CA2326198C (en) | Cosolvent formulations | |
| EP0487066A1 (en) | Disinfectant composition | |
| EP2747772B1 (en) | Ophthalmic formulations | |
| US20210401878A1 (en) | Stable Pharmaceutical Articles Containing Dilute Povidone Iodine Formulations | |
| MX2010012933A (es) | Composiciones farmaceuticas que contienen una droga antibiotica de fluoroquinolona. | |
| US20100203088A1 (en) | Silver Nanoparticle Dispersion Formulation | |
| NZ231238A (en) | Stabilising iodophor package containing additional iodine | |
| AU2013344497B2 (en) | Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | |
| CN113318122A (zh) | 一种含有聚维酮碘的消毒剂组合物及其用途 | |
| US20030109422A1 (en) | Process for the preparation of pharmaceutical formulations containing lactoferrin | |
| AU2002217319B2 (en) | Liquid antimicrobial compositions | |
| AU2010236505B2 (en) | Aqueous ophthalmic compositions containing anionic therapeutic agents | |
| Lokesh et al. | Role of Prostaglandins in Glaucoma: Design and Optimization | |
| CA3168186A1 (en) | Stable liquid dispersinb compositions | |
| RU2089183C1 (ru) | Антибактериальный препарат и способ его получения | |
| CN114306374A (zh) | 一种几丁质生物胶及其制备方法 | |
| Sikora et al. | A method for the obtaining of increased viscosity eye drops containing amikacin | |
| PROPERTIES | INFLUENCE OF ADDITIVES AND STORAGE TEMPERATURE ON PHYSICOCHEMICAL AND MICROBIOLOGICAL PROPERTIES OF EYE DROPS CONTAINING CEFAZOLIN. | |
| Bobde et al. | International Journal of Pharmaceutical and Phytopharmacological Research (eIJPPR) | |
| JPS635091A (ja) | 着色防止方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 114443 Country of ref document: FI |
|
| MA | Patent expired |